Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here is one stock where Wall Street’s excitement appears well-founded and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
Allegro MicroSystems (ALGM)
Consensus Price Target: $54.82 (63.3% implied return)
The result of a spinoff from Sanken in Japan, Allegro MicroSystems (NASDAQ: ALGM) is a designer of power management chips and distance sensors used in electric vehicles and data centers.
Why Are We Cautious About ALGM?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Already-low operating margin of 2% fell over the last five years, and the smaller profit dollars make it harder to react to unexpected market developments
- Low free cash flow margin of 8.1% declined over the last five years as its investments ramped, giving it little breathing room
Allegro MicroSystems’s stock price of $33.57 implies a valuation ratio of 29.8x forward P/E. To fully understand why you should be careful with ALGM, check out our full research report (it’s free).
Veralto (VLTO)
Consensus Price Target: $114.79 (20.1% implied return)
Spun off from Danaher in 2023, Veralto (NYSE: VLTO) provides water analytics and treatment solutions.
Why Are We Hesitant About VLTO?
- Sales trends were unexciting over the last five years as its 4.6% annual growth was below the typical industrials company
- Projected sales growth of 6.6% for the next 12 months suggests sluggish demand
Veralto is trading at $95.54 per share, or 21.2x forward P/E. If you’re considering VLTO for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Globus Medical (GMED)
Consensus Price Target: $103.23 (36.6% implied return)
With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE: GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.
Why Are We Fans of GMED?
- Steady constant currency growth over the past two years shows the company can pursue its global ambitions, even in uncertain economic times
- Earnings growth has trumped its peers over the last five years as its EPS has compounded at 18.3% annually
- Free cash flow margin expanded by 8 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $75.56 per share, Globus Medical trades at 14.6x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
